Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
37 hedge funds and large institutions have $17.1M invested in Acura Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
39% more call options, than puts
Call options by funds: $43K | Put options by funds: $31K
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
12% more funds holding
Funds holding: 33 → 37 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $19.4M → $17.1M (-$2.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$92.6K |
| 2 |
Jane Street
New York
|
+$46.1K |
| 3 |
Morgan Stanley
New York
|
+$44.8K |
| 4 |
IB
Intrust Bank
Wichita,
Kansas
|
+$41.6K |
| 5 |
Millennium Management
New York
|
+$33.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$57.8K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$54K |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$41.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$36K |
| 5 |
FWP
FAS Wealth Partners
Leawood,
Kansas
|
-$17.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
HighTower Advisors
Chicago,
Illinois
| $15K | +$17.4K | +2,000 | New |
|
27
Barclays
London,
United Kingdom
| $9K | – | – | – |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $7K | -$57.8K | -6,659 | -88% |
|
29
Wells Fargo
San Francisco,
California
| $4K | – | – | – |
|
30
Bank of America
Charlotte,
North Carolina
| $3K | -$547 | -63 | -13% |
|
31
Citigroup
New York
| $3K | -$156 | -18 | -4% |
|
32
Group One Trading
Chicago,
Illinois
| $3K | +$3.13K | +360 | +379% |
|
33
AllianceBernstein
Nashville,
Tennessee
| $2K | – | – | – |
|
34
BNP Paribas Financial Markets
Paris,
France
| $99 | – | – | – |
|
35
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | – | – | – |
|
|
BIT
36
BlackRock Institutional Trust
San Francisco,
California
| – | -$54K | -6,423 | Closed |
|
|
U
37
UBS
Zurich,
Switzerland
| – | -$41.6K | -4,793 | Closed |
|
|
38
Citadel Advisors
Miami,
Florida
| – | -$36K | -4,302 | Closed |
|
ACUR Hedge Fund Activity: Q1 2014 in Review
37 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q1 2014, worth a combined $17.1M — down 12% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ACUR positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $92.6K. The largest seller was Tower Research Capital (TRC), cutting an estimated $57.8K.
- 37 institutional investors held Acura Pharmaceuticals (ACUR) as of Q1 2014, up from 33 in Q4 2013.
- Funds reported $17.1M of Acura Pharmaceuticals stock for Q1 2014, down 12% quarter-over-quarter.
- 7 funds opened new Acura Pharmaceuticals positions in Q1 2014 and 3 closed out, a net change of +4 holders.
- The largest Acura Pharmaceuticals buyer in Q1 2014 was Vanguard Group, an estimated $92.6K added.
- The largest Acura Pharmaceuticals seller in Q1 2014 was Tower Research Capital (TRC), an estimated $57.8K sold.
Based on aggregated 13F filings for Q1 2014.